Vimarsana
Biggest News Aggregation in the World

Page 9 - Uzzing Stocks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Uzzing Stocks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Uzzing Stocks Today - Breaking & Trending Today

UBS issues 'sell' tag on Bajaj Finance before housing unit board meet over listing - Vimarsana News

UBS issues 'sell' tag on Bajaj Finance before housing unit board meet over listing

UBS analysts shared a target price of Rs 6,800 per share for Bajaj Finance, implying 6 percent downside from current level

PSP Projects share gains 4% on launching Rs 244-crore QIP - Vimarsana News

PSP Projects share gains 4% on launching Rs 244-crore QIP

PSP Projects has set a floor price of Rs 682.59 a share for for the QIP but may offer a discount of up to 5 percent

Gujarat State Petronet falls sharply from day's high as tariff cut triggers flurry of downgrades - Vimarsana News

Gujarat State Petronet falls sharply from day's high as tariff cut triggers flurry of downgrades

The sharp tariff cut, which poses a threat to GSPL's financial performance, prompted brokerages such as Kotak, Nuvama, Emkay Global and ICICI Securities to downgrade the stock

BNP Paribas initiates 'outperform' rating on Doms Industries, sets target price at Rs 1,950 - Vimarsana News

BNP Paribas initiates 'outperform' rating on Doms Industries, sets target price at Rs 1,950

DOMS, a top school stationery and art materials firm in India, has doubled sales twice in recent years without hefty ad spending. Popular with kids, its success stems from innovation and in-house manufacturing, offering value and strong margins. BNP Paribas predicts growth in current and new product lines.

Zydus Life gains over 3% on launch of bladder control drug - Vimarsana News

Zydus Life gains over 3% on launch of bladder control drug

Incred Equities estimates Mirabegron to be a $75-80 million opportunity for Zydus Lifesciences, as the company also enjoys a 180-day exclusivity period